What is the mechanism of action for sorafenib in the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

Sorafenib targets serine/threonine and receptor tyrosine kinases, including those of Raf, VEGFR-2, VEGFR-3, PDGFR-beta, c-KIT, fmslike tyrosine kinase–3 (FLT-3); and the glial cell-line–derived neurotrophic factor receptor (RET). A study by Verma et al concluded that the use of tyrosine kinase inhibitors reduces the incidence of brain metastasis among patients with metastatic renal cell carcinoma. [57]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!